Background: The use of supportive granulocyte colony-stimulating factor (G-CSF) to reduce the risk of neutropenic complications in high-risk cancer patients is consistently recommended by several clinical practice guidelines. However, in a previous meta-analysis, G-CSF prophylaxis was associated with an increased risk of secondary malignancies while reducing long-term mortality. We present here an updated systematic review and meta-analysis.
Introduction
Mutagenic and immunosuppressive effects of chemotherapy and radiotherapy treatment increase the risk of secondary malignancies, which are often life-threatening [1] [2] [3] [4] . Recently, the number of patients developing secondary malignancies has risen and, therefore, appropriate management is becoming increasingly important in long-term patient care [1] .
Neutropenia is a common hematological side-effect associated with chemotherapy, often leading to dose reductions and treatment delays [5] . Granulocyte colony-stimulating factor (G-CSF) reduces the severity and duration of neutropenic complications associated with chemotherapy, including febrile neutropenia and chemotherapy-induced neutropenia [5, 6] .
G-CSF support to reduce risk of neutropenic complications in high-risk cancer patients is recommended by clinical practice guidelines [7] [8] [9] , and may improve disease control and survival by minimizing dose reductions and treatment delays. In addition, G-CSF support may enable administration of full-dose chemotherapy in a shorter time interval (dose-dense regimens) and increased chemotherapy dose within the standard schedule (dose escalation), and may enable addition or substitution of additional chemotherapeutic agents to the standard regimen.
A previous meta-analysis of randomized controlled trials (RCTs) comparing chemotherapy in cancer patients with and without G-CSF support showed G-CSF administration was associated with decreased risk of all-cause mortality. However, patients receiving G-CSF support also experienced increased risk of secondary malignancies, including secondary acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) [10] .
We carried out an updated systematic literature review to determine the impact of primary G-CSF support on delivered dose intensity, mortality, and secondary malignancy risk in cancer patients receiving chemotherapy for solid tumors or malignant lymphoma.
Materials and methods

Literature search
A systematic literature review and meta-analysis including RCTs of G-CSF support in adult patients receiving chemotherapy was previously carried out for studies published between January 1990 and October 2008 [10] , and up to August 2012 in an updated review [11] . For the current update, a comprehensive literature search was carried out to include data published between the cut-off in the previous review (September 2012) All identified clinical practice guidelines from the National Guideline Clearinghouse, and conference proceedings from the American Society of Clinical Oncology and American Society of Hematology, published between 2014 and 2016, were searched for guidance on the use of myeloid growth factors. Additionally, a hand-search for additional published or unpublished material was carried out. The reference lists of key papers and systematic reviews identified through the electronic searches were also checked for relevant publications. No language restrictions were placed on the literature search.
Study selection
Relevant publications were identified according to best practice principles and reported in compliance with Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) requirements. Full papers were obtained and assessed independently by two investigators according to pre-defined eligibility criteria. Any disagreement between investigators was resolved by discussion.
Eligible studies were RCTs of cancer patients receiving conventional-dose chemotherapy for solid tumors or malignant lymphoma, who were randomized to primary G-CSF support or a control group without initial G-CSF treatment. The eligible studies were required to report survival measures (OS, all-cause mortality, or progression-free survival) or incidence of secondary malignancies (including AML or MDS), with a minimum followup time of 24 months. Where secondary malignancies were reported, the chemotherapy dosage and/or OS were also required to be reported.
There was no restriction on G-CSF use following the initial treatment cycle in the control group, based on cross-over study designs or secondary use. Following the initial treatment cycle, patients in the control arm of eligible studies may have received no G-CSF, G-CSF at the discretion of the treating physician, or secondary use of G-CSF.
The exclusion criteria included: nonrandom assignment of patients to treatment groups; G-CSF administered from the start of chemotherapy treatment in all study arms; use of granulocyte macrophage colony-stimulating factor; chemotherapy regimens in study arms that differed by more than one agent; inclusion of patients that had received stem cell or bone marrow transplantation, or a prior diagnosis of leukemia of any type. Other study types, such as review articles or economic analyses, were also excluded. Where duplicate publications of a study were identified, only the most recent reference reporting the desired outcomes was included.
Data extraction and quality assessment
Data were extracted from the full papers by two independent assessors using a data extraction form developed and agreed a priori. Discordant results were resolved by a third reviewer. In alignment with the previous literature reviews, studies were categorized into one of the four groups, based on the chemotherapy regimen and study design:
Group 1: studies in which patients received identical regimens (drugs, doses, and schedule) in each arm of the study, with the exception of G-CSF administration initially in one arm. Group 2: studies comparing a conventional or standard chemotherapy regimen (control) with a dose-dense regimen, defined as the same drugs and doses given at a shorter interval but usually to the same total dose of drugs with G-CSF support. Group 3: studies comparing a conventional or standard regimen (control) with a dose-escalated regimen with G-CSF support, in order to increase the dose of one or more of the same chemotherapy drugs, generally given in the same schedule or interval but often to a greater cumulative dose of drug(s). Group 4: studies in which patients are randomized to a conventional or standard regimen (control) or the same regimen with the substitution or addition of, at most, one myelosuppressive agent thought to provide a more intensive combination with the addition of G-CSF support.
Statistical methods
Cochran's Q statistic and the inconsistency index (I 2 ) were used to evaluate study heterogeneity. Cochran's Q represents the weighted sum of squared differences between individual study effects and the pooled effect across studies [12] . I 2 is defined as:
where df is the degrees of freedom and can be thought of as the proportion of variation across studies due to heterogeneity, rather than chance [13] . A qualitative assessment of the risk of bias was carried out using the Cochrane Collaboration tool [14] . Congress abstracts were excluded from this assessment as they generally contain inadequate information to allow an informed evaluation.
A meta-analysis was then conducted to evaluate the rates of allcause mortality and secondary malignancies in the eligible studies. Survival was calculated using the reported total number of deaths due to any cause at the end of the follow-up period. Where the number of deaths was not reported, an estimate was produced using the following calculation:
where N is the total number of patients per treatment arm in each study, and S(t) is the overall survival rate at the end of the followup, which was captured using the Kaplan-Meier survivor function estimate. However, this estimate cannot be named 'mortality' as it includes censored patients. Since this calculation was used for all studies without reported deaths and for both G-CSF and control arms, the over-estimation is balanced when comparing the two arms, assuming that the censoring patterns were the same for all studies and between the two arms. The relative risk (RR) and absolute risk difference (ARD) were calculated between the G-CSF arm and the control arm across the four study design groups. Summary effect estimates of the RR and ARD for mortality [95% confidence interval (CI)] were based on the method of Mantel and Haenszel, using a random-effects model as described by DerSimonian and Laird [15] . Summary estimation across trials was conducted using statistical software R (R Foundation). Forest plots were produced to display the point estimates and 95% confidence limits for RR for each study, along with weighted summary estimates across studies, with weights inversely proportional to the estimated variance for each study.
Results
Eligible studies
A PRISMA diagram for the study search and selection process is shown in supplementary Figure S1 , available at Annals of Oncology online. A total of 2604 publications were initially identified, with duplicate reports removed and a preliminary screen of titles, abstracts, and keywords carried out. Full papers of the remaining 179 publications were obtained for further evaluation and assessment. Fourteen studies met the inclusion criteria and were combined with those identified in the previous systematic literature searches [10, 11] for inclusion in the meta-analysis (supplementary Figure S1 , available at Annals of Oncology online). The updated meta-analysis included 68 studies, with 71 comparisons carried out as results from some studies were split into multiple comparisons.
Descriptive analysis
Characteristics of studies identified in the original literature review and subsequent update have previously been described in detail [10, 11] and are summarized in supplementary Appendix and Table S1 , available at Annals of Oncology online. In brief, 14 new studies were identified in the current literature search, including 6124 patients, although 2 studies did not report the total sample size. Chemotherapy was administered with primary G-CSF support in 3051 patients and without primary G-CSF support in 3073 patients.
Nine of the 14 studies reported OS and were included in the updated meta-analysis for mortality risk. Two studies reported incidence of secondary malignancies (including AML and MDS); however, only data from one study were included in the updated meta-analysis of secondary malignancy risk. The second study was excluded as the control arm did not include chemotherapy treatment.
Death occurred in 1171 patients randomized to receive GCSFs, compared with 1174 patients in control arms. However, one study did not report the number of deaths.
Meta-analysis
Study heterogeneity. Significant heterogeneity was observed for all-cause mortality, but not for secondary malignancies, across the 14 studies in the estimation of the RR (supplementary Table  S2 , available at Annals of Oncology online).
Risk of bias. Excluding congress abstracts, eight full publications met inclusion criteria and were assessed for risk of bias. Of these, five studies were considered to have high risk of bias, for reasons including inadequate blinding, selective reporting of results, and insufficient information for evaluation. Sensitivity analyses carried out to evaluate how excluding these studies affects the results did not alter study conclusions.
Mortality. The updated meta-analysis, including data from all 68 eligible studies, showed that survival was significantly improved in patients receiving primary G-CSF support, compared with patients who did not (mortality RR¼0.92; 95% CI 0.90-0.95; ARD¼À3.3%; 95% CI À4.2-À2.4; P < 0.0001). Numbers needed to treat are presented in supplementary Table S3 , available at Annals of Oncology online.
Study design groups 2, 3, and 4 also had significant RRs for mortality, favoring primary G-CSF support (supplementary Table S4 , available at Annals of Oncology online). Mortality RR for patients receiving G-CSF support was 0.86 (95% CI 0.80-0.92; P < 0.0001) in group 2, 0.92 (95% CI 0.85-0.99; P < 0.05) in Group 3, and 0.94 (95% CI 0.89-0.99; P < 0.05) in group 4 ( Figure 1 ). Mortality RR in group 1 was 0.97, suggesting a trend toward reduced mortality in patients who received supportive G-CSF, although this effect was not statistically significant (95% CI 0.93-1.01; P ¼ 0.0978). Based on the reported and extracted data, it was not possible to draw conclusions regarding differences in OS between reference and biosimilar G-CSF formulations.
Dead/ Total
G-CSF
Secondary malignancies. Two studies reported on the occurrence of secondary malignancies, including AML and MDS. In the first study, two patients in the control group reported AML or MDS versus nine patients receiving dose-dense chemotherapy and primary G-CSF support. In the second study, secondary malignancies were reported by 4% of patients receiving chemotherapy with primary G-CSF support and 5% of patients in the control group, which did not include chemotherapy treatment.
The updated meta-analysis indicated that occurrence of secondary malignancies was significantly higher in patients assigned to primary G-CSF support, compared with patients in control groups (RR¼1.85; 95% CI 1.19-2.88; ARD¼0.47; 95% CI 0.21-0.73; P<0.01) (Figure 2A ). Sensitivity analyses carried out excluding studies with zero secondary malignancies did not alter study conclusions ( Figure 2B ).
The number needed to treat to observe 1 secondary malignancy was 213 (P ¼ 0.00017) for all 25 studies used for secondary malignancy analysis. Excluding the studies with zero malignancies, the number needed to treat was 167 (P ¼ 0.00012). Since the number of patients who needed to be treated with G-CSF to avoid one death was 29 (P < 0.0001), for every death avoided 0.135 secondary malignancies occurred (data from all 25 studies). This value was 0.172 when the studies with zero malignancies were excluded. For every secondary malignancy observed, 7.4 deaths were avoided (data from all 25 studies). The number of deaths avoided was 5.8 when the studies with zero malignancies were excluded.
Discussion
This updated systematic literature review and meta-analysis presents results from 68 RCTs (71 separate comparisons) involving nearly 31 000 patients with solid tumors or lymphoma randomized to receive chemotherapy with or without primary G-CSF support, with a minimum of 24 months follow-up. The updated meta-analysis confirms that risk of all-cause mortality is lower in patients receiving chemotherapy with primary G-CSF Figure 2 . Risk ratios for secondary malignancies (AML/MDS) presented as forest plots for all eligible studies (A) and excluding studies with zero cases of secondary malignancies (B). New studies are highlighted in bold. AML, acute myeloid leukemia; CI, confidence interval; G-CSF, granulocyte colony-stimulating factor; MDS, myelodysplastic syndrome; RE, random effects.
support, compared with patients receiving chemotherapy alone (RR¼0.92; 95% CI 0.90-0.95; P < 0.0001).
The statistically significant reduction of mortality risk observed in this updated overview is in line with both earlier metaanalyses, with primary G-CSF-supported chemotherapy associated with greater reductions in overall mortality, compared with no primary G-CSF support [10, 11] . In studies with a longer follow-up period, greater reductions in risk for all-cause mortality were observed [11] .
Although some reduction in risk of all-cause mortality was seen with addition of G-CSF to the chemotherapy regimen, improved disease control is the most likely explanation for the improvement in survival reported in this meta-analysis. Primary G-CSF support may enable administration of dose-dense, doseescalation, and intensified chemotherapy regimens, leading to increased disease control and a consequent reduction in mortality, compared with no G-CSF support.
This updated meta-analysis revealed a significantly higher risk of developing secondary malignancies in patients receiving primary G-CSF support, compared with controls (RR¼1.85; 95% CI 1.19-2.88; P < 0.01). Although these findings are consistent with results from the initial meta-analysis, the trend previously reported by Lyman et al. [10] was not statistically significant (RR¼1.01; 95% CI 0.78-1.30; P ¼ 0.941). It is of note that some studies reported no events; however, it is unclear whether these studies did not report secondary malignancies or if they specifically reported zero secondary malignancies. We believe that there is not enough information to exclude the studies and that investigators should report secondary malignancies as standard. A sensitivity analysis confirmed that excluding these studies did not alter study conclusions.
Potential limitations of this meta-analysis include that it is possible that not all relevant publications were identified, as journals may be indexed incorrectly or not indexed. However, it is unlikely that any large, high-quality RCTs would not be included in mainstream literature databases. There is also potential for publication bias; results from some clinical trials may not published.
Another limitation is that a number of patients in the control treatment arm of included studies were likely to have received G-CSF treatment after the first chemotherapy cycle, as permitted by the study or off-protocol. Consequently, exposure to G-CSFs among the control patients in these studies cannot be excluded. Patients enrolled into the RCTs included here may have been selected to exclude patients with certain comorbidities or poor performance. However, the previous meta-analysis found similar favorable effects on all-cause mortality, regardless of treatment intent, disease stage, and in studies in elderly patients [11] .
Several studies in this meta-analysis do not stratify for antibiotic use and have no protocol standards for anti-infective prophylaxis. Physicians may be more likely to use other anti-infective prophylaxes in more heavily treated patients, which is a potential confounding factor.
It was not possible to distinguish whether the risk of secondary malignancies is associated with supportive G-CSF use or the leukemogenic effects of intensified chemotherapeutic agents. Although greater risk of secondary malignancies may be Figure 2 . Continued primarily related to increased dose of chemotherapeutic agents with known leukemogenic potential, an enhanced leukemogenic effect of chemotherapy drugs by G-CSF cannot be confirmed based on this meta-analysis. However, the reduced overall mortality risk in patients receiving G-CSF-supported chemotherapy is reassuring.
Conclusions
Our findings confirm a modest but statistically significant increase in survival in patients undergoing intensified chemotherapy with primary G-CSF support for solid tumors and lymphoma, compared with those receiving standard chemotherapy. This is likely mediated via an indirect effect of G-CSF on disease control, compared with patients not receiving G-CSF support. Primary G-CSF support was also associated with a higher risk of developing secondary malignancies.
